Medical/Pharmaceuticals
Tigermed Reports Full Year 2024 Results
HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...
2025-03-27 18:48
3547
DeepCare Unveils Game-Changing Dental AI Agent at IDS 2025
COLOGNE, Germany, March 27, 2025 /PRNewswire/ -- From March 25 to 29, 2025, DeepCare, a global leader in dental AI, showcases its Multimodal Dental AI Agent and newly upgraded CBCT AI features at the International Dental Show (IDS 2025) inCologne, Germany. As the world's largest and most influent...
2025-03-27 16:00
1859
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
* STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched onMarch 12, 2025 * Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program inAugust 2024 JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc.,...
2025-03-27 13:29
2031
Hyundai ADM Demonstrates Anti-Metastatic Effect of 'PenetriumTM' in TNBC Preclinical Study
– Simultaneous treatment of primary and metastatic tumors by eliminating pseudo-resistance SEOUL, South Korea, March 27, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant a...
2025-03-27 13:27
2534
AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States
TAIPEI, March 26, 2025 /PRNewswire/ -- AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that,AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I clinical trial inthe United States. The first subject w...
2025-03-27 00:00
1796
Keymed Biosciences Announces Annual Results of 2024
CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) Three new drug applications of Stapokibart...
2025-03-26 23:09
3030
Juncell Therapeutics to Present Preclinical Data on Innovative Pretreatment Regimen of TIL Therapy at AACR Annual Meeting 2025
SHANGHAI, March 26, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced that a preclinical study of innovative pretreatment regimen...
2025-03-26 21:23
1813
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea, March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-power...
2025-03-26 21:00
2149
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, March 26, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held inChicago, USA, from April 25-30, 2025. The AA...
2025-03-26 20:00
1984
Peijia Medical Announces 2024 Annual Results
HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year endedDecember 31, 2024 ("the Year") on March 25, 2025. Fin...
2025-03-26 20:00
3245
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering bi...
2025-03-26 19:16
2012
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals
2025-03-26 17:00
3188
GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies
PISCATAWAY, N.J., March 26, 2025 /PRNewswire/ -- GenScript Biotech Corporation (GenScript), a global leader in life sciences research, manufacturing technologies and production services, has been awarded the EcoVadis Bronze Medal for the second year in a row, recognizing its strong sustainability...
2025-03-26 14:49
1781
NUS researchers develop microneedle technology to accelerate diabetic wound healing
'Sponge-like' microneedle patches deliver bioactive ingredients and reduce inflammation in slow- and non-healing wounds SINGAPORE, March 26, 2025 /PRNewswire/ -- Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by ...
2025-03-26 14:21
2521
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutica...
2025-03-26 10:29
2926
CStone to Showcase Five Latest Research Achievements at AACR 2025
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place inChicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific ...
2025-03-26 08:15
2111
Complete Genomics Announces Partnership with BioTuring and the Go Optical STOmics microscope.
SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Complete Genomics
2025-03-25 21:00
1829
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovativein vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001, which utilizes lipid nanoparticle (LNP) technolog...
2025-03-25 19:00
1842
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Sci...
2025-03-25 19:00
1928
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
* Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY * Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY toRMB5,396.9 million * Added 151 new integrated projects, including 13 in late-stage and commercial stage ...
2025-03-25 18:30
2836
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 300 media titles]
2026-01-27 13:00
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
